Baker McKenzie advised Idorsia Ltd. (SIX: IDIA), a Swiss pharmaceutical research company, on entering into significant global research and development collaboration agreements with Viatris Inc. (NASDAQ: VTRS), a global healthcare company for global development and commercialization, under which Viatris will receive exclusive worldwide development and commercialization rights for two Phase 3 assets. 

Under the terms of the agreements, the development programs for selatogrel and cenerimod and certain personnel will be transferred to Viatris for an upfront payment of USD 350 million, potential development and regulatory milestone payments, as well as certain contingent additional sales milestone payments and tiered royalties. Idorsia will contribute up to USD 200 million in the next three years to the development of the two programs.

Baker McKenzie Switzerland advised Idorsia on relevant Swiss law matters. 

The Baker McKenzie team included Julia Schieber (partner, IP and Technology), Olha Demianiuk (partner, Corporate M&A), Christoph Stutz (partner, Employment & Compensation), Lukas Glanzmann (partner, Banking & Finance) and Matthias Courvoisier (partner, Capital Markets). 
Explore Our Newsroom